Article Sidebar

Submitted
Feb 11, 2025
Published
Feb 11, 2025
Download
PDF
Statistic
Read Counter : 20 Download : 20

Main Article Content

Abstract

Hypertension remains a prevalent and significant risk factor for cardiovascular diseases globally, necessitating effective and evolving treatment strategies. Contemporary pharmacological management of hypertension has shifted toward personalized therapy, emphasizing the use of novel drug classes alongside traditional agents. Current antihypertensive strategies include the use of renin-angiotensin-aldosterone system (RAAS) inhibitors, calcium channel blockers, beta-blockers, and diuretics, often in combination, to optimize blood pressure control. Newer agents, such as direct renin inhibitors, angiotensin receptor blockers (ARBs) with enhanced efficacy, and selective aldosterone antagonists, have expanded treatment options, especially for patients with coexisting conditions like diabetes and chronic kidney disease. Additionally, the integration of fixed-dose combination therapies has improved adherence and patient outcomes. Personalized medicine, guided by genetic and phenotypic factors, further refines treatment regimens, ensuring better tolerability and effectiveness. As research continues, novel biomarkers and non-pharmacological interventions are also being explored to complement pharmacological therapies, ultimately aiming for a more holistic and effective approach to hypertension management.


          

Keywords

Renin-angiotensin-aldosterone system Personalized medicine Fixed-dose combinations Cardiovascular risk Novel antihypertensive agents

Article Details

How to Cite
Shaik Parveen, K. Pavithra, K. Pranaya Rani, & B. Abhinav Raghavendra. (2025). Contemporary Strategies In The Pharmacological Management Of Hypertension. International Journal of Research in Pharmacology & Pharmacotherapeutics, 14(1), 111-118. Retrieved from https://ijrpp.com/ijrpp/article/view/625
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. WHO. Hypertension. World Health Organisation. https://www.who.int/news-room/fact-sheets/detail/hypertension. Published 2019. Accessed 2 October 2020. [Google Scholar]
  2. 2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure Hypertension. 2003; 42:1206–52. [Google Scholar]
  3. 3. Krause T, Lovibond K, Caulfield M, McCormack T, Williams B. on behalf of the Guideline Development Group. Management of hypertension: summary of NICE guidance. BMJ 2011; 343: d4891.
  4. 4. Wiysonge C, Bradley H, Myose B, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007; 1:CD002003.
  5. 5. Dzau, V.J.; Balatbat, C.A. Future of Hypertension. Hypertension 2019, 74, 450–457. [Google Scholar] [CrossRef] [PubMed]
  6. 6. DiMasi, J.A.; Grabowski, H.G.; Hansen, R.W. Innovation in the pharmaceutical industry: New estimates of R&D costs. J. Health Econ. 2016, 47, 20–33. [Google Scholar] [PubMed] [Green Version]
  7. 7. Hunter, P.G.; FChapman, A.; Dhaun, N. Hypertension: Current trends and future perspectives. Br. J. Clin. Pharmacol. 2021, 87, 3721–3736. [Google Scholar] [CrossRef] [PubMed]
  8. 8. Park, S.H.; Zhang, Y.; Rogers, J.A.; Gallon, L. Recent advances of biosensors for hypertension and nephrology. Curr. Opin. Nephrol. Hypertens. 2019, 28, 390–396. [Google Scholar] [CrossRef] [PubMed]
  9. 9. Whelton, P.K.; Carey, R.M.; Aronow, W.S.; Casey, D.E., Jr.; Collins, K.J.; Himmelfarb, C.D.; de Palma, S.M.; Gidding, S.; Jamerson, K.A.; Jones, D.W.; et al, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2018, 71, e127–e248. [Google Scholar] [PubMed]
  10. 10. Verdecchia, P.; Angeli, F. The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure: The weapons are ready. Rev. Esp. Cardiol. 2003, 56, 843–847. [Google Scholar] [CrossRef]
  11. 11. Struthers, A.; Krum, H.; Williams, G.H. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin. Cardiol. 2008, 31, 153–158. [Google Scholar] [CrossRef] [PubMed]
  12. 12. Tam, T.S.; Wu, M.H.; Masson, S.C.; Tsang, M.P.; Stabler, S.N.; Kinkade, A.; Tung, A.; Tejani, A.M. Eplerenone for hypertension. Cochrane Database Syst. Rev. 2017, 2, CD008996. [Google Scholar] [CrossRef] [PubMed]
  13. 13. Carey, R.M.; Calhoun, D.A.; Bakris, G.L.; Brook, R.D.; Daugherty, S.L.; Dennison-Himmelfarb, C.R.; Egan, B.M.; Flack, J.M.; Gidding, S.S.; Judd, E.; et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement from the American Heart Association. Hypertension 2018, 72, e53–e90. [Google Scholar] [CrossRef]
  14. 14. Schiffrin, E.L. Vascular endothelin in hypertension. Vascul. Pharmacol. 2005, 43, 19–29. [Google Scholar] [CrossRef]
  15. 15. Angeli, F.; Verdecchia, P.; Reboldi, G. Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension. Cardiol. Ther. 2021, 10, 397–406. [Google Scholar] [CrossRef]
  16. 16. Zanchi, A.; Maillard, M.; Burnier, M. Recent clinical trials with omapatrilat: New developments. Curr. Hypertens. Rep. 2003, 5, 346–352. [Google Scholar] [CrossRef]
  17. 17. Sumners, C.; Peluso, A.A.; Haugaard, A.H.; Bertelsen, J.B.; Steckelings, U.M. Anti-fibrotic mechanisms of angiotensin AT2 -receptor stimulation. Acta Physiol. 2019, 227, e13280. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  18. 18. Symplicity HTN-2 Investigators; Esler, M.D.; Krum, H.; Sobotka, P.A.; Schlaich, M.P.; Schmieder, R.E.; Bohm, M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet 2010, 376, 1903–1909. [Google Scholar] [CrossRef]
  19. 19. Bhatt, D.L.; Kandzari, D.E.; O’Neill, W.W.; D’Agostino, R.; Flack, J.M.; Katzen, B.T.; Leon, M.B.; Liu, M.; Mauri, L.; Negoita, M.; et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014, 370, 1393–1401. [Google Scholar] [CrossRef] [Green Version]
  20. 20. 1Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018; 39(33): 3021–3104. [PubMed] [Google Scholar]
  21. 21. Hamdidouche I, Jullien V, Boutouyrie P, Billaud E, Azizi M, Laurent S. Drug adherence in hypertension: from methodological issues to cardiovascular outcomes. J Hypertens. 2017; 35(6): 1133–1144. [CAS] [PubMed] [Google Scholar]